Stifel has initiated coverage of Cytokinetics (CYTK) with a buy rating, citing its drug aficamten, valuation and upcoming ...

According to Stifel, the Meta partnership positions EssilorLuxottica at the forefront of the smart glasses revolution. The ...

CEO Ron Kruszewski and Yahoo Finance Executive Editor Brian Sozzi at the 2025 World Economic Forum in Davos, Switzerland, to talk about the macro issues impacting the investment banking firm, ...

Thursday, January 23, 2025, marks the release of a new report by Stifel analysts on the US transport sector. The report outlines a cautious perspective on the industry's future, noting that while 2024 ...

Stifel raised the firm’s price target on TFI International (TFII) to $147 from $139 and keeps a Hold rating on the shares. 2024 largely proved ...

With capacity declines driving more freight market gains than demand in 2025, FedEx Freight’s spin-off and march to more ...

Stifel raised the firm’s price target on Werner (WERN) to $35 from $30 and keeps a Hold rating on the shares. 2024 largely proved to be “the ...

Stifel Financial Corp. (NYSE: SF) will release its fourth quarter and full year 2024 financial results before the market ...

Stifel analyst Brian Brophy raised the firm’s price target on Quanta Services (PWR) to $388 from $374 and keeps a Buy rating ...

Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, ...

Stifel downgrades cybersecurity stocks Rapid7 and Tenable to Hold, citing cautious stance on vulnerability management.

Stifel CEO Ron Kruszewski discusses banks' M&A space and market valuation ahead of the new US administration's policy. Kruszewski speaks to Bloomberg's Lisa Abramowicz on the sidelines of the 2025 ...